- Home
- PMM vs SLGL Comparison
PMM vs SLGL Comparison
Compare PMM & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | SLGL |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 247.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PMM | SLGL |
|---|---|---|
| Price | $6.23 | $76.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 111.4K | 38.1K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | $27.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.70 | $0.41 |
| 52 Week High | $6.52 | $97.97 |
Technical Indicators
Market Signals| Indicator | PMM | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 49.10 |
| Support Level | $6.07 | $66.47 |
| Resistance Level | $6.36 | $93.21 |
| Average True Range (ATR) | 0.09 | 8.73 |
| MACD | 0.02 | -0.59 |
| Stochastic Oscillator | 83.74 | 43.92 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.